When multiple myeloma relapses

RESPOND with a treatment studied in 860 patients with relapsed multiple myeloma*

ENDEAVOR: a head-to-head phase 3 study1

Adapted from Dimopoulos et al.1


Multiple myeloma is a common and often fatal haematological malignancy, with new treatment options prolonging survival.1

Kyprolis® has been studied in combination with standard of care regimens to determine how it improves key efficacy endpoints.

Design:
The ENDEAVOR study was a randomised, head-to-head, open-label, multicentre, phase 3 study.1

Aim:
To compare the combination of Kyprolis® and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.1

Population:
929 patients with relapsed multiple myeloma who had received 1–3 previous therapeutic regimens.1

Primary endpoint: Progression-free survival.1

Secondary endpoints: Included overall survival, overall response (partial response or better), duration of response, incidence of grade 2 or higher peripheral neuropathy events, and safety.1

See the detailed treatment regimens in the ENDEAVOR study See the efficacy results from the ENDEAVOR study

*396 patients received KRd in the pivotal phase 3 ASPIRE study 2 and 464 patients received Kd in the head-to-head phase 3 ENDEAVOR study1

Please read the SmPC for full comprehensive safety information

References

  1. Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.
  2. Stewart AK et al. N Engl J Med 2015;372:142–152.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis